货号:GS40100
Brentuximab vedotin (Adcetris®) is a targeted antibody-drug conjugate (ADC) approved for treating specific CD30-positive lymphomas, primarily classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It consists of an anti-CD30 monoclonal antibody linked to the potent cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. The drug binds to CD30 on lymphoma cells, is internalized, and releases MMAE inside the cell, where it disrupts microtubules, arrests the cell cycle, and induces apoptosis. This targeted approach delivers chemotherapy directly to cancer cells while minimizing damage to healthy tissues.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物